{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:52:21Z","timestamp":1789199541010,"version":"build-2803163510"},"reference-count":33,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,1,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The prognosis of peripheral T-cell lymphoma (PTCL) is heterogenous. Baseline or interim imaging characteristics may inform risk-adapted treatment paradigms. We identified 112 patients with PTCL who were consecutively treated with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)\/CHOP-like regimens with the intent to consolidate with an autologous transplant. Baseline (n = 93) and interim (after 4 cycles, n = 99) positron emission tomography (PET) images were reevaluated, and we calculated baseline total metabolic tumor volume (TMTV). Interim PET (iPET) responses were graded visually by 5-point score (i5PS) and by percentage change of standardized uptake value. By univariate analysis, predictors of event-free survival (EFS) included Prognostic Index for Peripheral TCL (PIT) higher than 1 (hazard ratio [HR], 1.83; P = .021), International Prognostic Index (IPI) higher than 3 (HR, 2.01; P = .021), high TMTV (&amp;gt;125 cm3; HR, 3.92; P = .003), and positive iPET (HR, 3.57; P &amp;lt; .001). By multivariate analysis, high baseline TMTV predicted worse overall survival (OS; HR, 6.025; P = .022) and EFS (HR, 3.861; P = .005). Patients with i5PS of 1 to 3 had a longer median OS and EFS (104 months, 64 months) than those with i5PS of 4 to 5 (19 months, 11 months; P &amp;lt; .001). Four-year OS and EFS for patients with i5PS of 1 to 3 and PIT of 1 or less were 85% and 62%, respectively. However, 4-year OS and EFS for those with i5PS of 4 to 5 and PIT higher than 1 were both 0% (P &amp;lt; .001). In multivariate analysis, after controlling for IPI and PIT, i5PS was independently prognostic for EFS (HR, 3.400 95% confidence interval, 1.750-6.750; P &amp;lt; .001) and OS (HR, 10.243; 95% confidence interval, 4.052-25.891; P &amp;lt; .001). In conjunction with clinical parameters, iPET helps risk stratify patients with PTCL and could inform risk-adapted treatment strategies. Prospective studies are needed to confirm these findings.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018024075","type":"journal-article","created":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T16:55:36Z","timestamp":1548176136000},"page":"187-197","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":52,"title":["Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-0670","authenticated-orcid":false,"given":"Neha","family":"Mehta-Shah","sequence":"first","affiliation":[{"name":"Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Division of Oncology, Department of Medicine, Washington University in St. Louis, St. Louis, MO; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiteru","family":"Ito","sequence":"additional","affiliation":[{"name":"Molecular Imaging and Therapy Service, Department of Radiology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Bantilan","sequence":"additional","affiliation":[{"name":"Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J.","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Sauter","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6399-2006","authenticated-orcid":false,"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[{"name":"Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Sch\u00f6der","sequence":"additional","affiliation":[{"name":"Molecular Imaging and Therapy Service, Department of Radiology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,1,22]]},"reference":[{"issue":"25","key":"2020021108310672100_B1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020021108310672100_B2","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2020021108310672100_B3","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"issue":"25","key":"2020021108310672100_B4","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d\u2019Amore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020021108310672100_B5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"17","key":"2020021108310672100_B6","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","article-title":"How I treat the peripheral T-cell lymphomas","volume":"123","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2020021108310672100_B7","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.clml.2013.07.005","article-title":"A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission","volume":"13","author":"Mehta","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"20","key":"2020021108310672100_B8","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2017-06-788877","article-title":"Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma","volume":"130","author":"Moskowitz","year":"2017","journal-title":"Blood"},{"issue":"16","key":"2020021108310672100_B9","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2014-10-606939","article-title":"Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma","volume":"125","author":"Sauter","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2020021108310672100_B10","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"issue":"7","key":"2020021108310672100_B11","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"issue":"16","key":"2020021108310672100_B12","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020021108310672100_B13","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3109\/10428194.2010.529208","article-title":"Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010","volume":"51","author":"Meignan","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2020021108310672100_B14","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/S2352-3026(15)00002-2","article-title":"Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer\/T-cell lymphoma, nasal type: a multicentre, retrospective analysis","volume":"2","author":"Kim","year":"2015","journal-title":"Lancet Haematol"},{"issue":"4","key":"2020021108310672100_B15","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/annonc\/mdv010","article-title":"Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Horwitz","year":"2015","journal-title":"Ann Oncol"},{"issue":"10","key":"2020021108310672100_B16","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3109\/10428194.2013.767901","article-title":"18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma","volume":"54","author":"Casulo","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2020021108310672100_B17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12885-015-1193-1","article-title":"Prognostic significance of interim PET\/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma","volume":"15","author":"Jung","year":"2015","journal-title":"BMC Cancer"},{"issue":"2","key":"2020021108310672100_B18","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1038\/bcj.2016.2","article-title":"The prognostic value of interim and end-of-treatment PET\/CT in patients with newly diagnosed peripheral T-cell lymphoma","volume":"6","author":"Ham","year":"2016","journal-title":"Blood Cancer J"},{"issue":"3","key":"2020021108310672100_B19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00277-014-2227-5","article-title":"Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma","volume":"94","author":"Tomita","year":"2015","journal-title":"Ann Hematol"},{"issue":"4","key":"2020021108310672100_B20","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/annonc\/mdw011","article-title":"Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET\/CT in patients with peripheral T-cell lymphoma (PTCL)","volume":"27","author":"Cottereau","year":"2016","journal-title":"Ann Oncol"},{"issue":"4","key":"2020021108310672100_B21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2967\/jnumed.117.193946","article-title":"Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients","volume":"59","author":"Cottereau","year":"2018","journal-title":"J Nucl Med"},{"issue":"11","key":"2020021108310672100_B22","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.24128","article-title":"Utility of interim and end-of-treatment PET\/CT in peripheral T-cell lymphomas: A review of 124 patients","volume":"90","author":"El-Galaly","year":"2015","journal-title":"Am J Hematol"},{"issue":"2","key":"2020021108310672100_B23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2214\/AJR.09.3665","article-title":"Characterization of T-cell lymphomas by FDG PET\/CT","volume":"195","author":"Feeney","year":"2010","journal-title":"AJR Am J Roentgenol"},{"issue":"7","key":"2020021108310672100_B24","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1634\/theoncologist.2013-0463","article-title":"Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma","volume":"19","author":"Pellegrini","year":"2014","journal-title":"Oncologist"},{"issue":"27","key":"2020021108310672100_B25","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"23","key":"2020021108310672100_B26","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2020021108310672100_B27","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)","volume":"28","author":"Younes","year":"2017","journal-title":"Ann Oncol"},{"key":"2020021108310672100_B28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/blood.V128.22.184.184","article-title":"Prognostic value of baseline quantitative PET metrics for patients with unfavourable early stage Hodgkin lymphoma enrolled in the standard arm of the EORTC\/Lysa\/FIL H10 Trial","volume":"128","author":"Cottereau","year":"2016","journal-title":"Blood"},{"issue":"15","key":"2020021108310672100_B29","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","article-title":"Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma","volume":"22","author":"Cottereau","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"30","key":"2020021108310672100_B30","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2016.69.3747","article-title":"Metabolic tumor volume in lymphoma: hype or hope?","volume":"34","author":"Sch\u00f6der","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020021108310672100_B31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1095-0397(99)00016-3","article-title":"Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis","volume":"2","author":"Larson","year":"1999","journal-title":"Clin Positron Imaging"},{"issue":"4","key":"2020021108310672100_B32","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020021108310672100_B33","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2967\/jnumed.116.180406","article-title":"Baseline total metabolic tumor volume measured with fixed or different adaptive thresholding methods equally predicts outcome in peripheral T cell lymphoma","volume":"58","author":"Cottereau","year":"2017","journal-title":"J Nucl Med."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/2\/187\/1630760\/advances024075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/2\/187\/1630760\/advances024075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T08:54:38Z","timestamp":1581411278000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/2\/187\/246586\/Baseline-and-interim-functional-imaging-with-PET"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,22]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018024075","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,22]]}}}